DALLAS, Oct. 8, 2004 (PRIMEZONE) -- John Pentony, Publisher of TalkingStocks.com, announced today that the web site has released a new exclusive interview with Dr. Michael Szycher of CardioTech International, Inc. (AMEX:CTE). The interview is moderated by Dave Gentry, President of Aurelius Consulting Group in Maitland, Florida. In this interview, Dr. Szycher discusses in detail many of the company's exciting medical products, including a revolutionary polyurethane-based coronary artery bypass graft for the surgical treatment of coronary artery disease. CardioTech is presently the only company in the world that remains in clinical trials for a product of this type, as all of its competitors have been unsuccessful. CardioTech believes that its vast knowledge and expertise in polyurethane-based products will enable them to achieve success.
To listen to the interview in its entirety, please visit:
http://www.talkingstocks.com/interviews/CTE_100804.php
To learn more about CardioTech, please visit their website at:
http://www.cardiotech-inc.com/
About CardioTech International, Inc.
CardioTech International, Inc. (AMEX:CTE) develops and markets medical devices used in the treatment of late-stage cardiovascular disease. These products reduce risk, trauma, cost and the duration of surgical procedures. The company has developed a polyurethane-based coronary artery bypass graft for the surgical treatment of coronary artery disease, a market with an annual potential of $1.5 billion. CardioTech has also entered a $600 million annual market with its wound-dressing technologies. Fiscal 2004 revenues for CardioTech were up over 500 percent due to organic growth and the acquisition of GISH Biomedical in 2003.
About TalkingStocks.com
TalkingStocks.com offers exclusive interviews with key executives from publicly traded companies. TalkingStocks.com is owned by TalkingStocks.com LLC and is affiliated with StockGuru.com, one of the nation's top Internet destinations for small cap stock information. Our services include executive interviews, company profiles, investor calls and our "Ask The CEO" show. To feature your company, please call John Pentony, our Publisher at (972) 731-8621 or email john@talkingstocks.com.
Forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission.